Simultaneous Presentation of Secondary Adrenal Insufficiency and Primary Hypothyroidism due to Pembrolizumab: A Case Report

Checkpoint inhibitors have gained increased traction in recent years as they have improved prognosis in various malignancies. Pembrolizumab, an anti-programmed cell death protein (PD-1) monoclonal antibody, has become a first-line chemotherapeutic agent for stage II non–small cell lung cancer since...

Descripción completa

Detalles Bibliográficos
Autores principales: Khatri, Shivam, Alom, Mulham, Kashfi, Simon, Atallah, Jane, Goswami, Gayotri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467221/
https://www.ncbi.nlm.nih.gov/pubmed/37642143
http://dx.doi.org/10.1177/23247096231194401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467221/
https://www.ncbi.nlm.nih.gov/pubmed/37642143
http://dx.doi.org/10.1177/23247096231194401

Ejemplares similares